During the past year they’ve filed more than a dozen class actions against Cipro manufacturer Bayer Ag and generic drug companies, claiming they conspired to keep lower cost versions of the drug off the market.
While the Cipro cases are among a string of suits alleging antitrust violations by the pharmaceutical industry, the anxiety over anthrax has brought them to the forefront.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
